Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trialBrian G. Feagan, Dermot McGovern, Corey A. Siegel et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 28